Guggenheim analyst Michael Schmidt downgraded Boundless Bio (BOLD) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on BOLD: Boundless Bio Shifts Focus and Restructures Leadership Team Boundless Bio provides portfolio update Boundless Bio CMO Klaus Wagner, CBO Neil Abdollahian to depart Boundless Bio’s Q3 2024: Advancing Cancer Therapies Boundless Bio reports Q3 EPS (74c), consensus (75c) Disclaimer & DisclosureReport an Issue
